The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.

BACKGROUND Other than aspirin, there are few oral antithrombotic treatments with proven efficacy in patients with acute coronary syndrome. In this report, we present the rationale, design and baseline characteristics of the Clopidogrel in Unstable angina to prevent Recurrent ischaemic Events (CURE) trial, which includes a meta-analysis of the effects of thienopyridines in patients with vascular disease. METHODS AND RESULTS Combined data from randomized trials of thienopyrindines in patients with atherosclerotic disease demonstrated a 29% reduction in vascular events when compared with placebo/control (n=2392) (OR 0.71, 95% CI 0.58-0.86, P=0.0006) and a 10% reduction in vascular events when compared with aspirin (n=22 254) (OR 0.91, 95% Cl 0.84-0.99, P=0.039). Similarly, randomized trials of aspirin plus thienopyridines in patients undergoing intracoronary stenting, demonstrated a marked benefit of aspirin plus ticlopidine in reducing death or myocardial infarction compared with aspirin alone (OR 0.23, 95% CI 0.11-0.49, P=0.0001) or aspirin plus warfarin (OR 0.51, 95% CI 0.33-0.78, P=0.002). Whether these benefits extend to the much larger population of patients with acute coronary syndrome is unknown. CURE is an international, randomized, double-blind trial, in which patients with acute coronary syndrome will be randomized to receive either a bolus dose of clopidogrel (300 mg) followed by 75 mg per day for 3-12 months, or matching placebo. Both groups will receive aspirin. The co-primary efficacy end-points of CURE are: (1) the composite of cardiovascular death, myocardial infarction or stroke; and (2) the composite of cardiovascular death, myocardial infarction, stroke or refractory ischaemia. CURE will recruit approximately 12 500 patients with acute coronary syndrome (from 28 countries) and its power to detect moderate treatment benefits will be in the region of 80-90%, while maintaining an overall type I error (alpha) of 0.05. The baseline characteristics of the study population are consistent with at least a moderate risk group of patients with acute coronary syndrome. CONCLUSIONS Randomized trials of thienopyridines in patients with vascular disease demonstrate that thienopyridines are effective in reducing vascular events when compared with placebo/control or aspirin, as well as when used in combination with aspirin in patients undergoing intracoronary stent implantation. The CURE trial is a large international study to determine if acute and long-term treatment with the combination of clopidogrel and aspirin is superior to aspirin alone in patients with acute coronary syndrome.

[1]  M. Bertrand,et al.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000, Circulation.

[2]  A. Skene,et al.  Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. , 2000, Circulation.

[3]  W R Bell,et al.  Thrombotic thrombocytopenic purpura associated with clopidogrel. , 2000, The New England journal of medicine.

[4]  R. Califf,et al.  Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial , 2000, The Lancet.

[5]  R. Ligon,et al.  Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. , 1999, Journal of the American College of Cardiology.

[6]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[7]  J. Moses,et al.  Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. , 1999, Circulation.

[8]  A. Siegbahn,et al.  Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. , 1999, Lancet.

[9]  C. Macaya,et al.  Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). , 1998, Circulation.

[10]  E. Fleck,et al.  Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. , 1998, Circulation.

[11]  R. Falotico,et al.  The Antiaggregating and Antithrombotic Activity of Clopidogrel Is Potentiated by Aspirin in Several Experimental Models in the Rabbit , 1998, Thrombosis and Haemostasis.

[12]  C. Thalamas,et al.  A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. , 1998, Blood.

[13]  S. Yusuf,et al.  Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation , 1998, The Lancet.

[14]  J. Cazenave,et al.  The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. , 1998, Blood.

[15]  P. Yarnold,et al.  Thrombotic Thrombocytopenic Purpura Associated with Ticlopidine: A Review of 60 Cases , 1998, Annals of Internal Medicine.

[16]  V. Fuster,et al.  Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. , 1998, Circulation.

[17]  M. Bell,et al.  Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin). , 1998, American Journal of Cardiology.

[18]  Y. Kupfer,et al.  Ticlopidine and thrombotic thrombocytopenic purpura. , 1997, The New England journal of medicine.

[19]  P. Armstrong,et al.  Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. , 1997, The Canadian journal of cardiology.

[20]  J. Cazenave,et al.  The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells , 1997, FEBS letters.

[21]  P. Brunel,et al.  Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. , 1997, Journal of the American College of Cardiology.

[22]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.

[23]  A. Colombo,et al.  A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. , 1996, Circulation.

[24]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[25]  D. Bergqvist,et al.  Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS). , 1995, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[26]  G. Burnstock,et al.  Purinoceptors: are there families of P2X and P2Y purinoceptors? , 1994, Pharmacology & therapeutics.

[27]  J. Herbert,et al.  Clopidogrel, A Novel Antiplatelet and Antithrombotic Agent , 1993 .

[28]  K. Jakobs,et al.  ADP Receptor Induced Activation of Guanine Nucleotide Binding Proteins in Rat Platelet Membranes– An Effect Selectively Blocked by the Thienopyridine Clopidogrel , 1992, Thrombosis and Haemostasis.

[29]  J. Bertrand,et al.  Thrombotic thrombocytopenic purpura related to ticlopidine , 1991, The Lancet.

[30]  J. Maffrand,et al.  Ticlopidine and Clopidogrel (SR 25990C) Selectively Neutralize ADP Inhibition of PGE1-Activated Platelet Adenylate Cyclase in Rats and Rabbits , 1991, Thrombosis and Haemostasis.

[31]  C. Cimminiello,et al.  Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. , 1990, Circulation.

[32]  H. Adams,et al.  A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. , 1989, The New England journal of medicine.

[33]  F. Violi,et al.  Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. , 1989, The Journal of laboratory and clinical medicine.

[34]  V. Hachinski,et al.  THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE , 1989, The Lancet.

[35]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[36]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.